Health & Fitness
Health and Fitness
Health and Fitness
Wed, February 4, 2009
Tue, February 3, 2009 ACADIA Pharmaceuticals to Present at the BIO CEO & Investor Conference on February 10, 2009
SAN DIEGO--([ BUSINESS WIRE ])--ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the BIO CEO & Investor Conference 2009 on Tuesday, February 10, 2009, at 10:00 a.m. Eastern Time at The Waldorf=Astoria Hotel in New York City.
A live webcast of ACADIA's presentation will be accessible on the company's website, [ www.acadia-pharm.com ], under the investors section and an archived recording will be available on the website through February 24, 2009.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders. ACADIA is focused on developing a portfolio of its four most advanced product candidates, including pimavanserin in Phase III for Parkinson's disease psychosis, a product candidate in Phase II for chronic pain and a product candidate in Phase I for glaucoma, both in collaboration with Allergan, and ACP-106 in IND-track development. All of the product candidates in ACADIA's pipeline emanate from discoveries made using its proprietary drug discovery platform. ACADIA maintains a website at [ www.acadia-pharm.com ] to which ACADIA regularly posts copies of its press releases as well as additional information and through which interested parties can subscribe to receive email alerts.
